Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115129 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Immunopharmacology, 2025. Verfasst von HamidReza Mahmoudi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Lichen Planus, Janus Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: CinnaGen Co.
Abstract (Originalsprache)
BACKGROUND: Lichen planopilaris (LPP) is a chronic inflammatory disorder that affects hair follicles and leads to permanent hair loss. Managing LPP is challenging due to insufficient evidence on treatments' effectiveness. Janus kinase inhibitors have recently emerged as potential therapies for LPP. OBJECTIVES: This study aims to evaluate the efficacy of tofacitinib, a JAK inhibitor, compared to placebo in classic LPP. METHODS: A randomized, double-blind, placebo-controlled trial was conducted with 37 participants. Participants received either tofacitinib 5 mg daily or placebo along with topical clobetasol for six months. Both groups were followed for nine months. Outcome measures included the Lichen Planopilaris Activity Index, Physician's Global Assessment Score, Dermatology Life Quality Index, and adverse events. RESULTS: Our results demonstrated a significant improvement in the anagen pull test in the tofacitinib group compared to placebo, indicating treatment effectiveness. However, no significant difference was observed in the reduction of the Lichen Planopilaris Activity Index between the two groups. Tofacitinib also showed a significant decrease in physician global assessment scores over time compared to placebo. Adverse events were minimal, with no significant differences between groups. CONCLUSIONS: This study suggests that tofacitinib may effectively halt disease progression in LPP, emphasizing its potential as a treatment option.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: sahar.dadkhahfar@gmail.com.
- Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Förderung
- CinnaGen Co
Zitieren
APA
Mahmoudi, H., Daneshpajooh, M., Dadkhahfar, S., Robati, R. M., Tehranchinia, Z., Farokh, P., Shariatnia, M., Shahidi-Dadras, M., & Moravvej, H. (2025). Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115129
Vancouver
Mahmoudi H, Daneshpajooh M, Dadkhahfar S, Robati RM, Tehranchinia Z, Farokh P, et al. Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115129
BibTeX
@article{Mahmoudi2025,
author = {Mahmoudi, HamidReza and Daneshpajooh, Maryam and Dadkhahfar, Sahar and Robati, R M and Tehranchinia, Zohre and Farokh, Parisa and Shariatnia, Mohammad and Shahidi-Dadras, Mohammad and Moravvej, Hamideh},
title = {Efficacy and safety of tofacitinib in the treatment of adults with lichen planopilaris: A randomized placebo-controlled trial},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115129}
}
EUVIMED